Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Pain, Intractable × Dexmedetomidine × Clear all

Phase

Phase 2/3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain, Postoperative 3 Agnosia 2 Thyroid Neoplasms 1 Postoperative Analgesia 1 Pain, Intractable 1 Neoplasms 1 Neoplasm Metastasis 1

Interventions

Dexmedetomidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03936205 2019-05-14

Dexmedetomidine Addition to Morphine in Patients With Metastatic Cancer

Hotel Dieu de France Hospital

Phase 2/3 Completed

Neoplasm Metastasis, Pain, Intractable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡